Dapagliflozin—redefining treatment of T2DM?

被引：0

作者：

Edward C. Chao

机构：

[1] University of California,Division of Endocrinology and Metabolism

[2] San Diego and VA San Diego,undefined

来源：

Nature Reviews Endocrinology | 2011年 / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently, glycosuria has been regarded only as a consequence of T2DM, but dapagliflozin employs glycosuria as a mechanism of treatment. Will this paradigm shift gain acceptance?

引用

页码：696 / 697

页数：1

共 50 条

[1] DIABETES Dapagliflozin-redefining treatment of T2DM?
Chao, Edward C.
[J]. NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (12) : 696 - 697
[2] Safety of Dapagliflozin in Clinical Trials for T2DM
Ptaszynska, Agata
Johnsson, Kristina M.
Apanovitch, Anne Marie
Sugg, Jennifer E.
Parikh, Shamik J.
List, James F.
[J]. DIABETES, 2012, 61 : A258 - A259
[3] Genital Infections in Asian Patients with T2DM Receiving Dapagliflozin Treatment
Ji, Linong
Nishimura, Rimei
Cho, Young Min
Sjostrom, David
Johnsson, Kristina M.
Johnsson, Eva
[J]. DIABETES, 2015, 64 : A658 - A658
[4] Durability of Dapagliflozin Treatment Response in Patients With T2DM: 2-Year Results
Salsali, Afshin
Rohwedder, Katja
Mansfield, Traci
Martin, Paula
Wei, Li
Parikh, Shamik
[J]. DIABETES, 2012, 61 : A264 - A264
[5] Dapagliflozin associated with higher risk of ketoacidosis in T2DM patients
[J]. Reactions Weekly, 2022, 1900 (1) : 6 - 6
[6] Dapagliflozin Is Safe and Well Tolerated in Older Patients with T2DM
Mansfield, Traci
Fioretto, Paola
Ptaszynska, Agata
Yavin, Yshai
Apanovitch, Anne Marie
Johnsson, Eva
Parikh, Shamik J.
List, James F.
[J]. DIABETES, 2014, 63 : A71 - A71
[7] ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING
Moshel, S.
Vexberg, Hirsch M.
Shavit, O.
Toledano, Y.
[J]. VALUE IN HEALTH, 2018, 21 : S131 - S131
[8] Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM
Nada, Aml Mohamed
Younan, Mariam Adel
[J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2021, 12
[9] Dapagliflozin Pilot Study in Insulin-Resistant T2DM Patients
Wilding, John P. H.
Norwood, Paul
T'joen, Caroline
Bastien, Arnaud
List, James F.
Fiedorek, Fred T.
[J]. DIABETES, 2009, 58 : A129 - A129
[10] Dapagliflozin Attenuates Diabetic Nephropathy and the Activation of the Inflammasome in Mice with T2DM
Ye, Yumei
Birnbaum, Yochai
Yang, Hsiu Chiung
Bajaj, Mandeep
[J]. DIABETES, 2017, 66 : A136 - A136

← 1 2 3 4 5 →